etira
  • Home
  • Our Company
  • Our Science
  • Clinical Trial
  • Our Pipeline
  • Our Team
  • News
  • Contact
  • Menu Menu
  • LinkedIn
  • Home
  • Our Company
  • Our Science
  • Clinical Trial
  • Our Pipeline
  • Our Team
  • News
  • Contact

At etira, we seek to protect human life by making cancer a treatable disease.
We create cutting-edge smarter medicine. We fight harder.
We evolve.
We outsmart it. Outsmarting
Cancer Cancer fights.
Cancer mutates.
Cancer is smart.

Slide We are Etira.
An ultra-dedicated team of relentless scientists who have reimagined therapies against cancer. entire scientists Our tireless efforts have led to a different kind of cancer treatment. One that destroys cancer from the inside out. One that is not limited by how much or how often cancer cells mutate or morph, because our treatment is smart enough to attack them in any form, giving hope back to patients suffering from metastatic cancers. Real hope.
Smarter therapies.

Slide Cancer
Disrupts
Lives Patients with METASTATIC OVARIAN CANCER
will die within the next 8 months. 13,270 Patients with METASTATIC BREAST CANCER
will die within the next 12 months. 43,700 Patients with METASTATIC PANCREATIC CANCER
will die within the next 12 months. 50,550 Patients will die within the next 12 MONTHS
from their cancers. 609,820 Patients with GLIOBLASTOMA
will die within the next 12 months. 18,990 Now it’s our turn to disrupt cancer. We are here to end this horrible disease that has ended life for so many. 


We will be the 
break through capable of breaking cancer apart. 



And an entirely new force of 
nature that makes 
life unstoppable.

Today we are preparing for the final fight against this destructive force. We will work tirelessly for you, for your family members, for happiness, life and love.
Cancer
doesn’t quit.
Neither
do we.

 

etira logo

 

Where to find us

Dallas Office:
3033 Irving Blvd,
Dallas. TX. 75247

Mailing Address:
3060 Pegasus Park Dr.
Dallas. TX. 75247

Scroll to top
Inclusion criteria:
  • Patients must be at least 18 years of age at the time of signing the informed consent.
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
  • Patients must have histologically or cytologically confirmed solid tumor, primarily including but not limited to breast, ovarian, pancreatic, endometrial, and hepatocellular carcinoma, that is advanced unresectable and/or metastatic disease for whom standard therapies do not exist or are no longer effective
  • Patients must have measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
  • Adequate baseline organ function and hematologic function
  • Life expectancy >3 months
Exclusion criteria
  • Systemic anti-cancer therapy within 4 weeks of first dose of study drug
  • Major surgery (as defined by the Investigator) within 4 weeks of first dose of study drug.
  • Uncontrolled intercurrent illnesses
  • Known history of LIPA deficiency, such as Wolman disease or Cholesterol ester storage disease.